[{"id":"0db89e9b-db2b-43cc-83d7-77deb9d111cd","acronym":"SCOUT","url":"https://clinicaltrials.gov/study/NCT02637687","created_at":"2021-01-17T17:20:37.992Z","updated_at":"2025-02-25T12:26:24.234Z","phase":"Phase 1/2","brief_title":"A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children","source_id_and_acronym":"NCT02637687 - SCOUT","lead_sponsor":"Bayer","biomarkers":" NTRK3 • ETV6 • NTRK","pipe":" | ","alterations":" NTRK positive • NTRK fusion","tags":["NTRK3 • ETV6 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK positive • NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e carboplatin • Vitrakvi (larotrectinib) • pemetrexed • Rybrevant (amivantamab-vmjw) • Lazcluze (lazertinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 154","initiation":"Initiation: 12/16/2015","start_date":" 12/16/2015","primary_txt":" Primary completion: 07/20/2024","primary_completion_date":" 07/20/2024","study_txt":" Completion: 09/30/2026","study_completion_date":" 09/30/2026","last_update_posted":"2025-02-24"},{"id":"204cae00-5d2c-422e-af6c-ba51e68ea377","acronym":"CONNECT1903","url":"https://clinicaltrials.gov/study/NCT04655404","created_at":"2021-01-19T20:41:28.986Z","updated_at":"2025-02-25T14:15:44.274Z","phase":"Phase 1","brief_title":"A Pilot Study of Larotrectinib for Newly-Diagnosed High-Grade Glioma with NTRK Fusion","source_id_and_acronym":"NCT04655404 - CONNECT1903","lead_sponsor":"Nationwide Children's Hospital","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 15","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 12/01/2025","primary_completion_date":" 12/01/2025","study_txt":" Completion: 12/01/2025","study_completion_date":" 12/01/2025","last_update_posted":"2025-02-18"},{"id":"1c1d3f40-f2af-499a-b04e-123bc4d694d0","acronym":"ON-TRK","url":"https://clinicaltrials.gov/study/NCT04142437","created_at":"2021-01-18T20:13:13.808Z","updated_at":"2025-02-25T15:26:13.445Z","phase":"","brief_title":"Study to Learn More About the Safety and Effectiveness of the Drug VITRAKVI During Routine Use in Patients With TRK Fusion Cancer Which is Locally Advanced or Spread From the Place Where it Started to Other Places in the Body","source_id_and_acronym":"NCT04142437 - ON-TRK","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 150","initiation":"Initiation: 04/03/2020","start_date":" 04/03/2020","primary_txt":" Primary completion: 11/30/2029","primary_completion_date":" 11/30/2029","study_txt":" Completion: 03/31/2030","study_completion_date":" 03/31/2030","last_update_posted":"2025-02-10"},{"id":"f0aa223d-45fe-469e-a692-cb8949633296","acronym":"NAVIGATE","url":"https://clinicaltrials.gov/study/NCT02576431","created_at":"2021-01-17T17:25:20.190Z","updated_at":"2025-02-25T15:42:38.245Z","phase":"Phase 2","brief_title":"A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors","source_id_and_acronym":"NCT02576431 - NAVIGATE","lead_sponsor":"Bayer","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 215","initiation":"Initiation: 09/30/2015","start_date":" 09/30/2015","primary_txt":" Primary completion: 07/20/2025","primary_completion_date":" 07/20/2025","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-10"},{"id":"a960e964-3a5f-401a-844c-ae8dd61b3da6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03213704","created_at":"2023-12-06T19:15:43.766Z","updated_at":"2025-02-25T16:51:56.748Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With NTRK Fusions (A Pediatric MATCH Treatment Trial)","source_id_and_acronym":"NCT03213704","lead_sponsor":"National Cancer Institute (NCI)","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 9","initiation":"Initiation: 08/23/2017","start_date":" 08/23/2017","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 10/08/2025","study_completion_date":" 10/08/2025","last_update_posted":"2025-02-04"},{"id":"9019c921-3c37-404e-9dcf-6b18ca280688","acronym":"EPI VITRAKVI","url":"https://clinicaltrials.gov/study/NCT05236257","created_at":"2022-02-11T12:52:54.392Z","updated_at":"2025-02-25T17:12:08.743Z","phase":"","brief_title":"A Study Called EPI VITRAKVI to Compare Treatment Results in Patients With Infantile Fibrosarcoma (IFS), a Type of Connective Soft Tissue Cancer, Who Received a Treatment Called Larotrectinib From a Study Called SCOUT With Patient Data From an External Database","source_id_and_acronym":"NCT05236257 - EPI VITRAKVI","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 93","initiation":"Initiation: 03/10/2022","start_date":" 03/10/2022","primary_txt":" Primary completion: 09/13/2022","primary_completion_date":" 09/13/2022","study_txt":" Completion: 09/13/2022","study_completion_date":" 09/13/2022","last_update_posted":"2024-12-10"},{"id":"245c1786-d5c4-49a7-8439-75f183f39949","acronym":"","url":"https://clinicaltrials.gov/study/NCT05783323","created_at":"2023-03-24T16:04:14.237Z","updated_at":"2025-02-25T17:26:04.484Z","phase":"Phase 2","brief_title":"Larotrectinib to Enhance RAI Avidity in Differentiated Thyroid Cancer","source_id_and_acronym":"NCT05783323","lead_sponsor":"Children's Hospital of Philadelphia","biomarkers":" NTRK1 • NTRK3 • NTRK2 • NTRK","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 02/14/2024","start_date":" 02/14/2024","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-11-12"},{"id":"2a11f2ce-d7a1-4499-9adf-7f2d5fda7036","acronym":"ROSALINE","url":"https://clinicaltrials.gov/study/NCT04551495","created_at":"2021-01-18T21:45:49.585Z","updated_at":"2024-07-02T16:34:26.568Z","phase":"Phase 2","brief_title":"Neoadjuvant Study of Targeting ROS1 in Combination With Endocrine Therapy in Invasive Lobular Carcinoma of the Breast (ROSALINE)","source_id_and_acronym":"NCT04551495 - ROSALINE","lead_sponsor":"Jules Bordet Institute","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • HER-2 negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • letrozole • goserelin acetate"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 65","initiation":"Initiation: 01/14/2021","start_date":" 01/14/2021","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 10/01/2024","study_completion_date":" 10/01/2024","last_update_posted":"2024-06-13"},{"id":"8a3d3d41-a452-48ff-8178-8d754ba2fbf3","acronym":"","url":"https://clinicaltrials.gov/study/NCT05170204","created_at":"2021-12-27T15:54:25.891Z","updated_at":"2024-07-02T16:34:59.196Z","phase":"Phase 3","brief_title":"A Study Evaluating the Efficacy and Safety of Multiple Therapies in Cohorts of Participants With Locally Advanced, Unresectable, Stage III Non-Small Cell Lung Cancer (NSCLC)","source_id_and_acronym":"NCT05170204","lead_sponsor":"Hoffmann-La Roche","biomarkers":" PD-L1 • RET • ROS1","pipe":" | ","alterations":" RET fusion • ALK fusion • ROS1 fusion","tags":["PD-L1 • RET • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RET fusion • ALK fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • Rozlytrek (entrectinib) • Alecensa (alectinib) • Gavreto (pralsetinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 121","initiation":"Initiation: 11/01/2022","start_date":" 11/01/2022","primary_txt":" Primary completion: 06/17/2029","primary_completion_date":" 06/17/2029","study_txt":" Completion: 04/14/2035","study_completion_date":" 04/14/2035","last_update_posted":"2024-06-04"},{"id":"130047ee-0a8b-4a61-991a-4693497b26dc","acronym":"","url":"https://clinicaltrials.gov/study/NCT04879121","created_at":"2021-05-10T14:53:10.353Z","updated_at":"2024-07-02T16:35:05.353Z","phase":"Phase 2","brief_title":"Larotrectinib for the Treatment of NTRK Amplification Positive, Locally Advanced or Metastatic Solid Tumors","source_id_and_acronym":"NCT04879121","lead_sponsor":"M.D. Anderson Cancer Center","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":"","alterations":" ","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 13","initiation":"Initiation: 04/30/2021","start_date":" 04/30/2021","primary_txt":" Primary completion: 11/11/2025","primary_completion_date":" 11/11/2025","study_txt":" Completion: 11/11/2025","study_completion_date":" 11/11/2025","last_update_posted":"2024-05-07"},{"id":"dcc86dfa-5f1f-487e-97bd-3b553b98917f","acronym":"STARTRK-NG","url":"https://clinicaltrials.gov/study/NCT02650401","created_at":"2021-01-18T12:54:05.938Z","updated_at":"2024-07-02T16:35:12.285Z","phase":"Phase 1/2","brief_title":"Study Of Entrectinib (Rxdx-101) in Children and Adolescents With Locally Advanced Or Metastatic Solid Or Primary CNS Tumors And/Or Who Have No Satisfactory Treatment Options","source_id_and_acronym":"NCT02650401 - STARTRK-NG","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion • ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 69","initiation":"Initiation: 05/03/2016","start_date":" 05/03/2016","primary_txt":" Primary completion: 06/15/2025","primary_completion_date":" 06/15/2025","study_txt":" Completion: 06/15/2025","study_completion_date":" 06/15/2025","last_update_posted":"2024-03-29"},{"id":"8214fea8-a403-48c1-9fa6-030636cc99e1","acronym":"STARTRK-2","url":"https://clinicaltrials.gov/study/NCT02568267","created_at":"2021-01-17T17:20:53.382Z","updated_at":"2024-07-02T16:35:12.401Z","phase":"Phase 2","brief_title":"Basket Study of Entrectinib (RXDX-101) for the Treatment of Patients With Solid Tumors Harboring NTRK 1/2/3 (Trk A/B/C), ROS1, or ALK Gene Rearrangements (Fusions)","source_id_and_acronym":"NCT02568267 - STARTRK-2","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" ALK rearrangement • ROS1 rearrangement","tags":["ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ALK rearrangement • ROS1 rearrangement"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Xalkori (crizotinib) • Rozlytrek (entrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 534","initiation":"Initiation: 11/19/2015","start_date":" 11/19/2015","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 04/01/2025","study_completion_date":" 04/01/2025","last_update_posted":"2024-03-28"},{"id":"9eaee900-c56a-440b-bf3e-d9e5c14d97d5","acronym":"ADVL1823","url":"https://clinicaltrials.gov/study/NCT03834961","created_at":"2021-01-18T18:56:06.238Z","updated_at":"2024-07-02T16:35:13.156Z","phase":"Phase 2","brief_title":"Larotrectinib in Treating Patients With Previously Untreated TRK Fusion Solid Tumors and TRK Fusion Relapsed Acute Leukemia","source_id_and_acronym":"NCT03834961 - ADVL1823","lead_sponsor":"Children's Oncology Group","biomarkers":" NTRK1 • NTRK3 • NTRK2 • ETV6","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2 • ETV6"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 10/25/2019","start_date":" 10/25/2019","primary_txt":" Primary completion: 09/30/2024","primary_completion_date":" 09/30/2024","study_txt":" Completion: 09/30/2024","study_completion_date":" 09/30/2024","last_update_posted":"2024-03-22"},{"id":"0db68b48-63b4-415c-9bee-7380074c53b2","acronym":"","url":"https://clinicaltrials.gov/study/NCT05396859","created_at":"2022-05-31T12:54:45.824Z","updated_at":"2024-07-02T16:35:14.538Z","phase":"Phase 1","brief_title":"Entrectinib in Combination With ASTX727 for the Treatment of Relapsed/Refractory TP53 Mutated Acute Myeloid Leukemia","source_id_and_acronym":"NCT05396859","lead_sponsor":"OHSU Knight Cancer Institute","biomarkers":" TP53 • RUNX1 • MAPK1 • NTRK • MAPK3","pipe":" | ","alterations":" TP53 mutation • NTRK expression","tags":["TP53 • RUNX1 • MAPK1 • NTRK • MAPK3"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e TP53 mutation • NTRK expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib) • Inqovi (decitabine/cedazuridine)"],"overall_status":"Recruiting","enrollment":" Enrollment 12","initiation":"Initiation: 10/28/2022","start_date":" 10/28/2022","primary_txt":" Primary completion: 12/31/2024","primary_completion_date":" 12/31/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-15"},{"id":"4b52c1e0-7f02-447c-817c-f6773b95d1e0","acronym":"TRUST-II","url":"https://clinicaltrials.gov/study/NCT04919811","created_at":"2021-06-10T01:52:36.470Z","updated_at":"2024-07-02T16:35:19.277Z","phase":"Phase 2","brief_title":"Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC","source_id_and_acronym":"NCT04919811 - TRUST-II","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 224","initiation":"Initiation: 09/01/2021","start_date":" 09/01/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2027","study_completion_date":" 06/01/2027","last_update_posted":"2024-02-15"},{"id":"e41c6423-6ebc-477e-83c1-0ab041388c50","acronym":"DETERMINE","url":"https://clinicaltrials.gov/study/NCT05770544","created_at":"2023-03-15T14:02:36.092Z","updated_at":"2024-07-02T16:35:20.432Z","phase":"Phase 2/3","brief_title":"DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Teenage/Young Adults and Paediatric Patients With ROS1 Gene Fusion-positive Cancers.","source_id_and_acronym":"NCT05770544 - DETERMINE","lead_sponsor":"Cancer Research UK","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion • ROS1 positive","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion • ROS1 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 06/01/2024","start_date":" 06/01/2024","primary_txt":" Primary completion: 10/01/2029","primary_completion_date":" 10/01/2029","study_txt":" Completion: 10/01/2029","study_completion_date":" 10/01/2029","last_update_posted":"2024-02-07"},{"id":"0d144f9c-62b7-4fec-8e14-e3271c7c60fe","acronym":"LOXO-TRK-14001","url":"https://clinicaltrials.gov/study/NCT02122913","created_at":"2021-01-17T17:11:46.373Z","updated_at":"2025-02-25T17:07:27.905Z","phase":"Phase 1","brief_title":"A Study to Test the Safety of the Investigational Drug Larotrectinib in Adults That May Treat Cancer","source_id_and_acronym":"NCT02122913 - LOXO-TRK-14001","lead_sponsor":"Bayer","biomarkers":" NTRK","pipe":" | ","alterations":" NTRK fusion","tags":["NTRK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Vitrakvi (larotrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 75","initiation":"Initiation: 05/04/2014","start_date":" 05/04/2014","primary_txt":" Primary completion: 02/01/2017","primary_completion_date":" 02/01/2017","study_txt":" Completion: 04/09/2021","study_completion_date":" 04/09/2021","last_update_posted":"2023-11-06"},{"id":"eb70c6e6-301a-44ee-9150-3a7d0e444854","acronym":"TRUST","url":"https://clinicaltrials.gov/study/NCT04395677","created_at":"2021-01-17T17:16:15.961Z","updated_at":"2024-07-02T16:35:31.201Z","phase":"Phase 2","brief_title":"A Study of AB-106 in Subjects With Advanced NSCLC Harboring ROS1 Fusion Gene","source_id_and_acronym":"NCT04395677 - TRUST","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" ROS1","pipe":" | ","alterations":" ROS1 fusion","tags":["ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 173","initiation":"Initiation: 07/07/2020","start_date":" 07/07/2020","primary_txt":" Primary completion: 12/30/2023","primary_completion_date":" 12/30/2023","study_txt":" Completion: 12/31/2025","study_completion_date":" 12/31/2025","last_update_posted":"2023-10-30"},{"id":"455bb5f8-dfe6-4827-a577-3f71d18ec8ca","acronym":"","url":"https://clinicaltrials.gov/study/NCT04617054","created_at":"2021-01-19T20:33:44.655Z","updated_at":"2024-07-02T16:36:28.868Z","phase":"Phase 2","brief_title":"Basket Study of AB-106 for the Treatment of Patients With Solid Tumors With NTRK Fusion Gene","source_id_and_acronym":"NCT04617054","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" NTRK1 • NTRK3 • NTRK2","pipe":" | ","alterations":" NTRK1 fusion • NTRK3 fusion • NTRK2 fusion","tags":["NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e NTRK1 fusion • NTRK3 fusion • NTRK2 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 06/01/2021","start_date":" 06/01/2021","primary_txt":" Primary completion: 04/30/2024","primary_completion_date":" 04/30/2024","study_txt":" Completion: 12/31/2026","study_completion_date":" 12/31/2026","last_update_posted":"2021-06-21"},{"id":"e2bbfbbe-3093-4c31-aa02-f03910852aaf","acronym":"STARTRK-1","url":"https://clinicaltrials.gov/study/NCT02097810","created_at":"2021-01-17T17:16:52.712Z","updated_at":"2024-07-02T16:36:29.383Z","phase":"Phase 1","brief_title":"Study of Oral RXDX-101 in Adult Patients With Locally Advanced or Metastatic Cancer Targeting NTRK1, NTRK2, NTRK3, ROS1, or ALK Molecular Alterations.","source_id_and_acronym":"NCT02097810 - STARTRK-1","lead_sponsor":"Hoffmann-La Roche","biomarkers":" ALK • ROS1 • NTRK1 • NTRK3 • NTRK2","pipe":"","alterations":" ","tags":["ALK • ROS1 • NTRK1 • NTRK3 • NTRK2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Rozlytrek (entrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 84","initiation":"Initiation: 07/28/2014","start_date":" 07/28/2014","primary_txt":" Primary completion: 06/02/2020","primary_completion_date":" 06/02/2020","study_txt":" Completion: 06/02/2020","study_completion_date":" 06/02/2020","last_update_posted":"2021-06-09"},{"id":"8f3fcd9d-3554-40b3-abe4-2fc941420095","acronym":"","url":"https://clinicaltrials.gov/study/NCT02279433","created_at":"2021-01-18T10:44:10.387Z","updated_at":"2024-07-02T16:36:40.799Z","phase":"Phase 1","brief_title":"A First-in-human Study to Evaluate the Safety, Tolerability and Pharmacokinetics of DS-6051b","source_id_and_acronym":"NCT02279433","lead_sponsor":"AnHeart Therapeutics Inc.","biomarkers":" KRAS • ROS1 • NTRK1 • NTRK3 • NTRK2 • RAS","pipe":" | ","alterations":" RAS wild-type","tags":["KRAS • ROS1 • NTRK1 • NTRK3 • NTRK2 • RAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Ibtrozi (taletrectinib)"],"overall_status":"Completed","enrollment":" Enrollment 46","initiation":"Initiation: 09/01/2014","start_date":" 09/01/2014","primary_txt":" Primary completion: 03/01/2019","primary_completion_date":" 03/01/2019","study_txt":" Completion: 03/01/2019","study_completion_date":" 03/01/2019","last_update_posted":"2020-09-22"}]